BACKGROUND: A consensus has not been reached regarding the optimal pazopanib dosing schedule, which we determined in patients who received pazopanib at our Institution. PATIENTS AND METHODS: Twenty-five patients who were prescribed pazopanib between 2012 and 2015 were included in this retrospective analysis. RESULTS: The median progression-free survival (PFS) time was 7.7 months. This time (various doses) was similar to that achieved by high-dose pazopanib in the PALETTE study. The log-rank test revealed no significant differences in the PFS times between the low- and high-dose pazopanib groups, with the majority of patients receiving a dose of 400 mg, indicating that controlling the side-effects might be more critical than administering higher doses. CONCLUSION: Pazopanib should be started from a low dose with careful increase to avoid pazopanib-related side-effects, which is necessary to provide a balance between the life-prolonging effects of pazopanib and quality of life (QoL) of patients. Copyright
BACKGROUND: A consensus has not been reached regarding the optimal pazopanib dosing schedule, which we determined in patients who received pazopanib at our Institution. PATIENTS AND METHODS: Twenty-five patients who were prescribed pazopanib between 2012 and 2015 were included in this retrospective analysis. RESULTS: The median progression-free survival (PFS) time was 7.7 months. This time (various doses) was similar to that achieved by high-dose pazopanib in the PALETTE study. The log-rank test revealed no significant differences in the PFS times between the low- and high-dose pazopanib groups, with the majority of patients receiving a dose of 400 mg, indicating that controlling the side-effects might be more critical than administering higher doses. CONCLUSION:Pazopanib should be started from a low dose with careful increase to avoid pazopanib-related side-effects, which is necessary to provide a balance between the life-prolonging effects of pazopanib and quality of life (QoL) of patients. Copyright
Authors: Cody N Justice; Mohamed H Derbala; Tesla M Baich; Amber N Kempton; Aaron S Guo; Thai H Ho; Sakima A Smith Journal: J Cardiovasc Pharmacol Ther Date: 2018-04-29 Impact factor: 2.457
Authors: Vikas Dembla; Roman Groisberg; Ken Hess; Siqing Fu; Jennifer Wheler; David S Hong; Filip Janku; Ralph Zinner; Sarina Anne Piha-Paul; Vinod Ravi; Robert S Benjamin; Shreyaskumar Patel; Neeta Somaiah; Cynthia E Herzog; Daniel D Karp; Jason Roszik; Funda Meric-Bernstam; Vivek Subbiah Journal: Sci Rep Date: 2017-11-21 Impact factor: 4.379
Authors: Brian A Menegaz; Branko Cuglievan; Jalen Benson; Pamela Camacho; Salah-Eddine Lamhamedi-Cherradi; Cheuk Hong Leung; Carla L Warneke; Winston Huh; Vivek Subbiah; Robert S Benjamin; Shreyaskumar Patel; Najat Daw; Andrea Hayes-Jordan; Joseph A Ludwig Journal: Oncologist Date: 2017-12-06